Using in vitro metabolism data and clinical PK profiles of strong CYP inhibitors and inducers, full PBPK-DDI simulations quantitatively predict interaction risks for moderate and weak enzyme modulators. Validated modeling outputs can be submitted to regulators to support exemption from dedicated human clinical DDI trials, lowering development costs and shortening clinical research timelines for new molecular entities.